New Study Suggests Shingles Vaccine May Hold Key to Slowing Dementia Progression
A groundbreaking study published this week has found that getting vaccinated against shingles may not only delay the onset of dementia, but also potentially slow its progression. The research, which involved over 7 million people worldwide, adds to a growing body of evidence that vaccines can have a significant impact on our health as we age.
The study's findings are particularly exciting because they suggest that the shingles vaccine has therapeutic potential for those already living with dementia. According to Dr. Pascal Geldsetzer, the study's senior author, "the most exciting part is that this really suggests the shingles vaccine doesn't have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia."
Currently, Alzheimer's disease and other forms of dementia are among the leading causes of disability and death worldwide. With numbers projected to rise dramatically over the coming decades – with new cases expected to double from 500,000 in 2020 to over 1 million by 2060 in the US alone – any potential breakthroughs in prevention or treatment are a welcome development.
Shingles, which typically occurs years after a chickenpox infection, is characterized by a painful rash and can lead to persistent nerve pain. However, getting vaccinated against shingles has been shown to lower the risk of getting the disease itself, as well as its debilitating complications.
The new study found that people who received the shingles vaccine were significantly less likely to be diagnosed with mild cognitive impairment – a precursor to dementia – nine years later than those who did not receive the vaccine. Furthermore, among individuals already living with dementia, those who had been vaccinated against shingles were also more likely to survive for longer periods without succumbing to their condition.
The study's findings are based on data from a public health program in Wales that offered the shingles vaccine to people aged 79 or older when it began. Researchers were able to isolate the effect of vaccination by comparing those who turned 80 just before and after the program started – essentially creating a randomized trial with a control group.
The study's senior author noted that this unique design made the research "essentially like a randomized trial with a control group – those a little bit too old to be eligible for the vaccine, and an intervention group – those just young enough to be eligible." These findings are set to have significant implications for public health policy and could potentially lead to increased vaccination rates in older adults.
A groundbreaking study published this week has found that getting vaccinated against shingles may not only delay the onset of dementia, but also potentially slow its progression. The research, which involved over 7 million people worldwide, adds to a growing body of evidence that vaccines can have a significant impact on our health as we age.
The study's findings are particularly exciting because they suggest that the shingles vaccine has therapeutic potential for those already living with dementia. According to Dr. Pascal Geldsetzer, the study's senior author, "the most exciting part is that this really suggests the shingles vaccine doesn't have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia."
Currently, Alzheimer's disease and other forms of dementia are among the leading causes of disability and death worldwide. With numbers projected to rise dramatically over the coming decades – with new cases expected to double from 500,000 in 2020 to over 1 million by 2060 in the US alone – any potential breakthroughs in prevention or treatment are a welcome development.
Shingles, which typically occurs years after a chickenpox infection, is characterized by a painful rash and can lead to persistent nerve pain. However, getting vaccinated against shingles has been shown to lower the risk of getting the disease itself, as well as its debilitating complications.
The new study found that people who received the shingles vaccine were significantly less likely to be diagnosed with mild cognitive impairment – a precursor to dementia – nine years later than those who did not receive the vaccine. Furthermore, among individuals already living with dementia, those who had been vaccinated against shingles were also more likely to survive for longer periods without succumbing to their condition.
The study's findings are based on data from a public health program in Wales that offered the shingles vaccine to people aged 79 or older when it began. Researchers were able to isolate the effect of vaccination by comparing those who turned 80 just before and after the program started – essentially creating a randomized trial with a control group.
The study's senior author noted that this unique design made the research "essentially like a randomized trial with a control group – those a little bit too old to be eligible for the vaccine, and an intervention group – those just young enough to be eligible." These findings are set to have significant implications for public health policy and could potentially lead to increased vaccination rates in older adults.